NCT05921448View on ClinicalTrials.gov

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Influenza, Human
Interventions
BIOLOGICAL

Vaxigripetra

Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.

BIOLOGICAL

Flumist

Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).

Trial Locations (7)

2100

Copenhagen Hospital Biobank Unit, Department of Clinical Immunology, Rigshospitalet, Denmark, Copenhagen

Diagnostic Immunology, Department of Clinical Immunology, Rigshospitalet, Denmark, Copenhagen

Institute for Immunology and Microbiology (ISIM), Panum Institute, University of Copenhagen, Copenhagen

2300

National Influenza Center for WHO at Statens Serum Institut (SSI), Copenhagen

2800

Technical University of Denmark (DTU), Kongens Lyngby

2900

Department of Medicine, Section of Respiratory Medicine, Herlev and Gentofte Hospital, Gentofte Municipality

W12 0NN

Imperial College, London

All Listed Sponsors
collaborator

The Novo Nordic Foundation

OTHER

lead

Chronic Obstructive Pulmonary Disease Trial Network, Denmark

OTHER